International Assets Investment Management LLC Increases Holdings in IDEXX Laboratories, Inc. (NASDAQ:IDXX)

International Assets Investment Management LLC increased its stake in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 52,746.0% during the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 528,460 shares of the company’s stock after buying an additional 527,460 shares during the quarter. International Assets Investment Management LLC owned about 0.64% of IDEXX Laboratories worth $2,669,890,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in the stock. Atomi Financial Group Inc. lifted its position in IDEXX Laboratories by 3.4% during the first quarter. Atomi Financial Group Inc. now owns 637 shares of the company’s stock worth $344,000 after buying an additional 21 shares in the last quarter. Eads & Heald Wealth Management lifted its position in IDEXX Laboratories by 0.8% during the second quarter. Eads & Heald Wealth Management now owns 2,686 shares of the company’s stock worth $1,309,000 after buying an additional 22 shares in the last quarter. LRI Investments LLC lifted its position in IDEXX Laboratories by 21.7% during the second quarter. LRI Investments LLC now owns 129 shares of the company’s stock worth $63,000 after buying an additional 23 shares in the last quarter. Sovereign Financial Group Inc. lifted its position in IDEXX Laboratories by 5.1% during the third quarter. Sovereign Financial Group Inc. now owns 470 shares of the company’s stock worth $237,000 after buying an additional 23 shares in the last quarter. Finally, Mather Group LLC. raised its position in IDEXX Laboratories by 3.9% in the third quarter. Mather Group LLC. now owns 617 shares of the company’s stock valued at $312,000 after purchasing an additional 23 shares during the period. Hedge funds and other institutional investors own 87.84% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have commented on IDXX shares. Stifel Nicolaus reduced their target price on IDEXX Laboratories from $510.00 to $500.00 and set a “hold” rating on the stock in a research report on Thursday, October 10th. Piper Sandler reduced their target price on IDEXX Laboratories from $600.00 to $520.00 and set a “neutral” rating on the stock in a research report on Wednesday, August 14th. StockNews.com downgraded IDEXX Laboratories from a “buy” rating to a “hold” rating in a research report on Wednesday, July 10th. BTIG Research started coverage on IDEXX Laboratories in a research report on Thursday, July 25th. They issued a “buy” rating and a $580.00 target price on the stock. Finally, JPMorgan Chase & Co. reduced their target price on IDEXX Laboratories from $630.00 to $575.00 and set an “overweight” rating on the stock in a research report on Friday, October 11th. Three equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus price target of $574.13.

IDEXX Laboratories Trading Down 0.8 %

IDXX opened at $457.90 on Thursday. IDEXX Laboratories, Inc. has a 12 month low of $372.50 and a 12 month high of $583.39. The stock has a market capitalization of $37.82 billion, a price-to-earnings ratio of 44.33, a PEG ratio of 4.14 and a beta of 1.33. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.37 and a quick ratio of 1.03. The business has a fifty day moving average price of $486.11 and a 200 day moving average price of $490.23.

IDEXX Laboratories (NASDAQ:IDXX) last released its earnings results on Tuesday, August 6th. The company reported $2.44 EPS for the quarter, missing the consensus estimate of $2.88 by ($0.44). IDEXX Laboratories had a return on equity of 57.03% and a net margin of 22.34%. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $1.01 billion. During the same period in the previous year, the firm earned $2.67 earnings per share. The company’s revenue for the quarter was up 6.4% compared to the same quarter last year. Sell-side analysts expect that IDEXX Laboratories, Inc. will post 10.44 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.